BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed SCNLD catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:77f3455d62281442fc99@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:SCNLD P2 readout (est.): SCIB1 and iSCIB1+ in Melanoma Patients Rec
 eiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE St
 udy)
DESCRIPTION:SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With
  Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)\nNCT04079166 | P
 HASE2 | ACTIVE_NOT_RECRUITING | sponsor: Scancell Ltd\nPrimary completion 
 date (ESTIMATED)\; top-line results usually follow later.\nTicker SCNLD (c
 onfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT04079166\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04079166
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
